Search

Displaying results 1721 - 1730 of 1901 in total
  1. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults

  2. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [L46342,L46387] Later on, the FDA approved pegunigalsidase alfa for the treatment of adult patients with Fabry disease that same month.[L46432,L46437] … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular

  3. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023.

  4. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines

  5. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    [A255183] In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation.

  6. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.

  7. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. … By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,

    Categories: Vascular Endothelial Growth Factor Receptor 2 Antagonist, VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors
  8. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    Approvals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).

  9. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

  10. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.